U.S. markets close in 5 hours 46 minutes
  • S&P 500

    3,796.87
    -22.85 (-0.60%)
     
  • Dow 30

    31,186.73
    -83.36 (-0.27%)
     
  • Nasdaq

    12,800.83
    -196.92 (-1.52%)
     
  • Russell 2000

    2,191.39
    -16.41 (-0.74%)
     
  • Crude Oil

    62.01
    +0.73 (+1.19%)
     
  • Gold

    1,712.80
    -3.00 (-0.17%)
     
  • Silver

    26.06
    -0.33 (-1.26%)
     
  • EUR/USD

    1.2038
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    1.4710
    +0.0010 (+0.07%)
     
  • GBP/USD

    1.3972
    +0.0019 (+0.14%)
     
  • USD/JPY

    107.4680
    +0.4660 (+0.44%)
     
  • BTC-USD

    49,260.72
    -1,969.80 (-3.84%)
     
  • CMC Crypto 200

    988.00
    +0.79 (+0.08%)
     
  • FTSE 100

    6,631.38
    -44.09 (-0.66%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

BLUE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 15, 2021 /Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE) and certain of its officers, ... Bronstein, Gewirtz and Grossman, LLC

NEW YORK, NY / ACCESSWIRE / February 15, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired bluebird securities between May 11, 2020 and November 4, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/blue.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/blue or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in bluebird you have until April 13, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/629650/BLUE-Investor-Alert-Bronstein-Gewirtz-Grossman-LLC-Notifies-bluebird-bio-Inc-Investors-of-Class-Action-and-Encourages-Shareholders-to-Contact-the-Firm